InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,436.00
(
-0.73%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
71.97
(
0.37%
)
Bitcoin
64,452.19
(
-1.80%
)
Post# of 253252
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 97198

Thursday, 07/22/2010 9:01:05 AM

Thursday, July 22, 2010 9:01:05 AM

Post# of 253252
Re: Who's Who in All-Oral HCV Programs

I think we can now add ACHN to this list with the announcement of the NS5A inhibitor today. ACHN will also share with IDIX the important point of potentially having the only combo with the potential for QD dosing. Obviously, ACH-1625 does not work on all genotypes but the potential is there for ACH-2684 to do so.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up